From Bench to Bedside: What Physicians Need to Know About Endothelial Progenitor Cells

被引:24
|
作者
Mayr, Matthias [1 ]
Niederseer, David [1 ]
Niebauer, Josef [1 ]
机构
[1] Paracelsus Med Univ Salzburg, Inst Sports Med State Salzburg, Sports Med Olymp Ctr Salzburg Rif, Dept Sports Med Prevent & Rehabil, A-5020 Salzburg, Austria
来源
AMERICAN JOURNAL OF MEDICINE | 2011年 / 124卷 / 06期
关键词
Cardiovascular risk; Endothelial progenitor cells; Stem cells; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; MARROW-DERIVED CELLS; NEOINTIMA FORMATION; PERIPHERAL-BLOOD; IN-VIVO; POSTNATAL NEOVASCULARIZATION; CARDIOVASCULAR RISK; MIGRATORY ACTIVITY; AMI TRIAL;
D O I
10.1016/j.amjmed.2011.01.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Since the discovery of endothelial progenitor cells in 1997, the scientific world has seen their ups and downs. There has been much discussion about the detection methods of endothelial progenitor cells and their diagnostic and predictive value. A lack of standardized methods to define endothelial progenitor cells has led to a number of nomenclatures and measuring methods that are difficult for clinicians to oversee. Therefore, only specialized hematologists and cardiologists were aware of their existence. Now it is time for a change: Most of the controversies have been eliminated by elaborate studies. This review aims to give an overview to the clinically working physician about the measurement, diagnostic potential, predictive value, and therapeutic potential of endothelial progenitor cells. (C) 2011 Elsevier Inc. All rights reserved. The American Journal of Medicine (2011) 124, 489-497
引用
收藏
页码:489 / 497
页数:9
相关论文
共 50 条